IW-3300 clinical trials
Also written IW-3300.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses IW-3300 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IW-3300
- 2
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses IW-3300 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain SyndromeTerminatedPhase 2Ironwood Pharmaceuticals, Inc.NCT05740007Written as IW-3300 rectal foamHow we know
- A Study of Multiple-ascending Doses of IW-3300 in Healthy SubjectsCompletedPhase 1Ironwood Pharmaceuticals, Inc.NCT05362695Written as IW-3300How we know
- A Study of Single Ascending Doses of IW-3300 in Healthy VolunteersCompletedPhase 1Ironwood Pharmaceuticals, Inc.NCT05188261Written as IW-3300How we know